Document is current
Any future updates will be listed below
-
Authors
Pouyiourou, Maria https://orcid.org/0000-0001-9296-3784
Bochtler, Tilmann https://orcid.org/0000-0003-4162-7881
Pauli, Chantal
Moch, Holger https://orcid.org/0000-0002-7986-2839
Brobeil, Alexander
Pantel, Klaus https://orcid.org/0000-0001-5736-2772
Stenzinger, Albrecht https://orcid.org/0000-0003-1001-103X
Krämer, Alwin https://orcid.org/0000-0001-8232-9982
- License Information
-
More Information
Article History
Accepted: 10 July 2025
First Online: 4 August 2025
Competing interests
: T.B. has received travel support from F. Hoffmann-La Roche and served as study oncologist for the CUPISCO trial (which was sponsored by F. Hoffmann-La Roche). C.P. has received research funding from F. Hoffmann-La Roche and served as study pathologist for the CUPISCO trial. H.M. has received research funding and honoraria for lectures from, and has served as a consultant on data safety monitoring boards or advisory boards for Amgen, Astellas, AstraZeneca, Bayer, F. Hoffmann-La Roche, Merck and Stemline Therapeutics. K.P. has received honoraria from Eppendorf, Menarini, MSD, NRICH, Roche and Sysmex. A.S. has acted as adviser for Aignostics, Amgen, Astellas, AstraZeneca, Bayer, Beigene, Bristol Myers Squibb, Eli Lilly, Illumina, Incyte, Janssen, Jazz Pharmaceuticals, MSD, Novartis, Pfizer, Qlucore, Roche, Sanofi, Servier, Takeda and Thermo Fisher, and has received research funding from Bayer, Bristol Myers Squibb, Chugai and Incyte. A.K. has received research funding from Bristol Myers Squibb, F. Hoffmann-La Roche and Molecular Health; consulting fees, travel support and/or remuneration for advisory board participation from F. Hoffmann-La Roche; and served as study oncologist for the CUPISCO trial. M.P. and A.B. declare no competing interests.
